Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

(2020) Rong En Tay et al.   CANCER GENE THERAPY

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

(2020) Dmitriy Zamarin et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

(2020) David A. Reardon et al.   JAMA Oncology

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies

(2020) Stephen M. Ansell et al.   Blood Advances

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

(2019) Mary L. Disis et al.   JAMA Oncology

Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study

(2019) U A Matulonis et al.   ANNALS OF ONCOLOGY

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2019) Angel Garcia-Diaz et al.   Cell Reports

PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+T-Cell–Driven Antitumor Immunity

(2018) Sarah L. Buchan et al.   CLINICAL CANCER RESEARCH

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors

(2017) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Combination immunotherapy: a road map

(2017) Patrick A. Ott et al.   Journal for ImmunoTherapy of Cancer

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL INVESTIGATION

Inherited CD70 deficiency in humans reveals a critical role for the CD70–CD27 pathway in immunity to Epstein-Barr virus infection

(2016) Kazushi Izawa et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer

(2016) Ruea-Yea Huang et al.   OncoImmunology

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

(2015) Hideho Okada et al.   LANCET ONCOLOGY

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia

(2012) L. A. Vitale et al.   CLINICAL CANCER RESEARCH

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials

(2012) Thierry Gorlia et al.   EUROPEAN JOURNAL OF CANCER

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia

(2011) Joris M. van Montfrans et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER